Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01ERN
|
||||
| Former ID |
DIB006555
|
||||
| Drug Name |
MGluR5 antagonists (anxiety), Novartis
|
||||
| Synonyms |
MGluR5 antagonists (anxiety); MGluR5 antagonists (anxiety), Novartis
|
||||
| Indication | Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] | Investigative | [1] | ||
| Company |
Novartis AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
C(=O)(N1C(CCCC1)CC)c1cnc(c(c1)Cl)Nc1cnc(cc1)C
|
||||
| Target and Pathway | |||||
| Target(s) | Metabotropic glutamate receptor 5 | Target Info | Antagonist | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Huntington's disease | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group I pathway | |||||
| Endogenous cannabinoid signaling | |||||
| Reactome | G alpha (q) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| GPCRs, Class C Metabotropic glutamate, pheromone | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.